039200 - Oscotec, Inc.

039200 Summary

Biopharma

Stock Price & Overview

₩36,600 +700 (+1.95%) Close · Sep 4, 2026 KST

KOSDAQ | ₩KRW | Close: ₩36,600 ≈ US$26 · Market cap ₩1.4tn (≈ $1.0bn)

039200 Financial Statements

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Total Revenue	99.8	34.0	5.0	5.1	3.9	43.5	4.4	18.7	3.9	3.6	18.3
Cost of Revenue	1.9	2.2	2.0	2.0	2.0	1.9	2.1	2.4	1.7	1.5	9.9
Gross Profit	97.9	31.8	2.9	3.0	2.0	41.6	2.3	16.3	2.2	2.1	8.5
Selling, General & Administrative	18.2	13.1	10.7	8.3	7.3	7.2	6.7	3.1	3.2	2.2	5.8
Operating Income	52.1	-2.7	-32.7	-28.6	-28.1	1.6	-19.9	6.2	-5.8	-1.7	0.7
Finance Income	4.1	4.0	4.8	1.2	0.2	0.7	0.7	0.5	0.0	0.1	0.1
Finance Costs	2.3	4.2	4.9	0.3	0.1	0.7	1.2	1.3	0.5	0.8	0.9
Pretax Income	52.8	-1.1	-32.3	-28.0	-28.6	1.3	-22.7	5.2	-6.4	-4.9	0.3
Income Tax Expense	-1.6	0.5	-3.8	-0.2	0.0	3.3	2.3	0.9	—	-0.0	-0.1
Net Income	54.4	-1.6	-28.5	-27.8	-28.6	-2.0	-25.0	4.3	-6.4	-4.4	0.4
Total Comprehensive Income	55.7	-2.2	-28.5	-26.9	-26.8	-3.2	-24.8	5.1	-6.3	-4.0	0.6

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Total Assets	229.9	170.8	132.6	143.7	49.0	76.4	72.4	70.3	40.5	40.8	49.5
Current Assets	199.0	141.2	102.4	107.9	17.0	55.0	55.3	57.3	29.5	17.5	30.5
Cash & Cash Equivalents	15.2	13.1	8.0	5.5	10.6	5.8	49.2	26.4	19.7	3.3	2.1
Inventories	1.8	1.8	1.7	1.3	1.2	1.1	1.0	1.0	0.9	0.8	10.5
Trade Receivables	87.6	35.3	2.0	1.9	0.7	25.2	0.5	19.2	3.9	5.7	3.9
Non-current Assets	30.9	29.6	30.1	35.9	32.0	21.4	17.1	12.9	11.0	23.3	19.0
Property, Plant & Equipment	19.1	17.4	17.9	18.9	22.9	12.7	15.5	11.5	9.5	8.4	8.9
Intangible Assets	0.6	0.6	0.6	0.6	1.2	1.2	1.4	1.1	1.0	13.3	9.8
Total Liabilities	43.0	38.4	37.9	21.9	17.8	19.1	18.0	18.6	14.9	12.1	22.6
Current Liabilities	39.0	34.8	34.8	18.6	14.4	15.5	14.4	15.7	11.7	8.9	21.8
Non-current Liabilities	4.0	3.6	3.0	3.3	3.3	3.6	3.6	2.9	3.2	3.1	0.8
Total Equity	186.8	132.4	94.7	121.8	31.2	57.2	54.4	51.7	25.7	28.8	26.9
Share Capital	19.1	19.1	19.1	19.0	15.2	15.2	15.0	14.3	13.6	12.8	12.1
Retained Earnings	-90.9	-142.9	-143.6	-119.2	-94.8	-68.5	-65.4	-42.5	-46.2	-28.2	-22.2

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Cash from Operating Activities	8.3	-26.0	-22.0	-26.4	-8.8	-17.9	0.0	-5.1	-3.7	-3.4	0.6
Cash from Investing Activities	-4.1	-0.3	13.4	-99.6	6.8	-24.4	1.8	-7.9	2.8	5.9	-10.4
Cash from Financing Activities	-1.9	30.3	11.1	120.3	6.3	-1.0	20.8	19.3	17.9	-1.3	10.1
Net Change in Cash	2.1	5.2	2.4	-5.1	4.8	-43.4	22.9	6.7	16.4	1.2	0.3

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Revenue	52.6	3.6	78.9	8.9	10.0	1.9	2.3	29.1	1.6	1.1
Cost of Revenue	0.4	0.5	0.6	0.6	0.5	0.4	0.6	0.7	0.5	0.4
Gross Profit	52.2	3.1	78.4	8.4	9.5	1.6	1.7	28.4	1.0	0.6
Selling, General & Administrative	13.5	13.1	7.1	3.5	3.3	4.4	0.4	4.5	4.9	3.3
Operating Income	38.7	-10.0	61.4	-0.4	-0.6	-8.3	-7.0	19.6	-7.4	-8.0
Finance Income	1.5	1.2	1.1	1.0	1.1	1.0	1.0	1.1	0.9	1.0
Finance Costs	2.0	0.7	-0.7	0.6	1.9	0.5	1.8	1.5	0.8	0.1
Pretax Income	40.8	-4.9	62.3	0.7	-2.4	-7.7	-6.5	19.4	-7.1	-6.9
Income Tax Expense	0.0	-0.0	-1.8	0.1	-0.1	-0.0	0.4	0.1	0.3	-0.3
Net Income	40.8	-5.0	64.0	0.6	-2.5	-7.8	-6.9	19.3	-7.3	-6.6
Total Comprehensive Income	41.3	-4.5	65.7	0.6	-2.8	-7.8	-5.9	19.0	-8.0	-7.3

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Assets	267.2	222.3	229.9	154.1	158.0	163.3	170.8	171.2	122.6	125.7
Current Assets	235.5	190.9	199.0	125.4	129.2	134.1	141.2	142.1	92.6	95.5
Cash & Cash Equivalents	32.4	13.1	15.2	14.9	19.1	26.6	13.1	17.9	2.6	6.0
Inventories	2.1	1.6	1.8	1.8	1.8	1.8	1.8	1.5	1.8	1.8
Trade Receivables	21.3	28.9	87.6	13.7	10.8	2.4	35.3	29.4	1.5	0.7
Non-current Assets	31.7	31.5	30.9	28.7	28.8	29.2	29.6	29.2	30.1	30.3
Property, Plant & Equipment	23.5	19.4	19.1	16.8	17.0	17.0	17.4	17.2	17.7	17.9
Intangible Assets	0.5	0.6	0.6	0.6	0.5	0.7	0.6	0.6	0.6	0.6
Total Liabilities	43.1	39.8	43.0	31.2	36.0	38.6	38.4	33.2	42.6	38.1
Current Liabilities	38.7	35.6	39.0	28.8	33.7	36.2	34.8	29.6	39.1	34.9
Non-current Liabilities	4.4	4.3	4.0	2.4	2.3	2.4	3.6	3.6	3.5	3.2
Total Equity	224.1	182.5	186.8	122.9	122.1	124.7	132.4	138.0	80.1	87.6
Share Capital	19.1	19.1	19.1	19.1	19.1	19.1	19.1	19.1	19.1	19.1
Retained Earnings	-56.9	-93.6	-90.9	-151.1	-150.7	-148.8	-142.9	-137.9	-154.8	-149.1

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Cash from Operating Activities	49.8	48.0	0.7	-7.9	-9.9	25.4	-8.1	-6.0	-6.3	-5.7
Cash from Investing Activities	-30.9	-50.6	1.2	3.0	3.7	-12.0	-7.2	3.3	-0.0	3.6
Cash from Financing Activities	-0.2	-0.0	-1.9	0.1	0.0	0.0	9.2	18.4	2.8	-0.1
Net Change in Cash	18.6	-2.7	0.3	-4.1	-7.6	13.5	-4.8	15.3	-3.4	-2.0

Consolidated (CFS), from DART. 11 fiscal years and 10 quarters. Accounts matched on IFRS account_id, not Korean labels, so the same line holds across years where the Korean wording changed. Quarterly figures are three-month values: income quarters from DART's three-month column, cash-flow quarters differenced from DART's cumulative figures, and Q4 as annual minus nine-month cumulative.

039200 Growth

FY2025 ₩bn	Latest	1-yr	3-yr CAGR	5-yr CAGR	10-yr CAGR
Revenue	99.8	+193.6%	+170.2%	+18.1%	+18.5%
Operating income	52.1	—	—	+101.2%	+54.2%
Net income	54.4	—	—	—	+65.0%
EPS	₩1,422	—	—	—	+65.0%
Operating cash flow	8.3	—	—	—	+29.1%
Shareholders' equity	186.8	+41.2%	+15.3%	+26.7%	+21.4%

Compound annual growth from the DART annual statements on this page. n/m where either end of the period is a loss or missing. EPS uses today's share count for every year.

039200 Profitability

Ratio	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Gross margin	98.1%	93.5%	59.0%	60.0%	50.0%	95.6%
Operating margin	52.2%	-8.0%	-659.6%	-565.7%	-719.9%	3.6%
Net margin	54.5%	-4.7%	-575.4%	-548.6%	-732.6%	-4.7%
Return on equity	34.1%	-1.4%	-26.3%	-36.3%	-64.7%	-3.7%
Return on assets	27.2%	-1.0%	-20.6%	-28.8%	-45.6%	-2.8%
Operating cash flow / revenue	8.3%	-76.6%	-445.3%	-521.9%	-224.5%	-41.1%

Margins divide by revenue for the same year. Return on equity and assets divide net income by the average of that year's and the prior year's balance, as DART reports them (consolidated, including minority interests).

Similar to 039200

Symbol	Last Price
140410Mezzion Pharma Co., Ltd.	₩65,000 +0.0%
068760Celltrion Pharm, Inc.	₩40,850 +0.0%
007390Naturecell Co., Ltd.	₩23,950 +0.2%
006280GC Biopharma Corp.	₩127,600 +0.5%
950160Kolon Tissue Gene, Inc.	₩17,100 +1.1%
069620Daewoong Pharma	₩116,100 +1.1%
290650L & C BIO Co., Ltd.	₩47,900 -1.4%
127120JS Link	₩33,600 +12.4%
475830Orum Therapeutics, Inc.	₩55,900 +2.6%
195940HK inno.N Corporation	₩42,050 +0.7%

Compare all 48 in Biopharma

What a US investor should know

Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
Daily limitKorean stocks can move at most ±30% in a session before trading halts.
Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.